Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration.

Temozolomide and capecitabine (TemCap) combination chemotherapy is a widely adopted option for the treatment of patients diagnosed with advanced neuroendocrine neoplasms (NENs) [[2]], and recent randomised phase II data support its use, especially in pancreatic neuroendocrine tumours [[4]]. On completion of the first 6 cycles of treatment, 63.3% of the patients ( I n i = 38) were free-of progression and therefore suitable for continuation of TemCap until disease progression (maintenance TemCap). 1. a Waterfall plot showing the best radiological objective response achieved in each individual patient (all patients with at least one radiological response available are shown; n = 53 patients). [Extracted from the article]